Melanin is a major determinant of skin pigmentation, synthesized by melanocytes within melanosomes. The variation in skin color in various population groups can be attributed to the number of melanosomes, distribution of melanin units in the epidermis of the skin, and the degree of melanization. The normal pigmentation in the skin is influenced by various factors such as the location and amount of melanin present, thickness of the horny layer of the skin, degree of vascularity, and the presence of carotene. Pigmentation disorders are caused either due to the excessive production of melanin known as hyper-pigmentation or lack of production of it in the melanocytes, known as hypo-pigmentation. Factors causing pigmentation disorders can be genetic, chemical factors, infections, tumors, and endocrine, among others.
The global pigmentation disorders treatment market is anticipated to grow during the forecast period, owing to increase in demand for non-invasive procedures which would dominate the market; growing awareness among people about esthetics, technological advances, rise in beauty consciousness among both men and women, and increase in prevalence of pigmentation disorders, among others. According to the American Academy of Dermatology, 5 million to 6 million women and over 50% to 75% of pregnant women in the U.S. are affected by melasma. Over 80% of pregnant women in Mexico suffer from melasma. Vitiligo is known to affect 1.3% of the total population. Furthermore, according to the American Society for Aesthetic Plastic Surgery (ASAPS), non-invasive modes of treatment are gaining popularity, and laser therapies, intense pulse light therapies, and chemical peels are the most preferred modes of treatment. Chemical peel therapy was the fifth most preferred treatment mode in 2016 and over 616,225 procedures were performed in the U.S. However, lack of reimbursement in certain regions, high cost of treatment, and the number of sessions required for the treatment is likely to have a negative impact on the growth of the market.
The global pigmentation disorders treatment market can be segmented based on treatment type, disease indication, end-user, and region. In terms of treatment type, the market can be categorized into pharmacological and cosmetic. The pharmacological segment can be sub-segmented into topical drugs, L-ascorbic acid, hydroquinone, and others. The cosmetic segment can be divided into laser therapy, microdermabrasion, chemical peels, and others. The cosmetic segment is anticipated to expand at a significantly high CAGR during the forecast period. This can be attributed to increase in demand for less invasive and non-invasive procedures, and faster and effective treatment. Based on disease indication, the global pigmentation disorders treatment market can be classified into hypo-pigmentation and hyper-pigmentation. Hypo-pigmentation can be sub-segmented into vitiligo, albinism, and others. Hyper-pigmentation can be sub-divided into melasma, post-inflammatory hyperpigmentation, solar lentigines, and others. In terms of end-user, the market can be categorized into hospitals, clinics, specialty dermatology centers, home-use, and others.
Geographically, the global pigmentation disorders treatment market can be segmented into five regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America accounted for the largest share of the global market in terms of revenue in 2016 and the trend is anticipated to continue during the forecast period. Strong growth in the region can be attributed to increase in the prevalence of pigmentation disorders in the region. Europe is expected to be the second leading market for pigmentation disorders treatment. However, the sluggish economy in the region is likely to negatively impact the growth of the market. The market in Asia Pacific is anticipated to record a significantly high CAGR owing to factors such as rise in patient population, growing government focus on enhancing health care facilities, and increase in product approvals.
Request for an in-depth table of contents for this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=34418
Leading players operating in the global pigmentation disorders treatment market are Pierre Fabre Laboratories, Bayer AG, Obagi Medical Products, Inc., SkinCeuticals International, Allergan, Inc., Alvogen, Inc., Cynosure, Inc., Ellipse A/S, and Episciences, Inc., among others.